

Yuya Seko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4147574/publications.pdf>

Version: 2024-02-01

61
papers

2,279
citations

304368

22
h-index

223531

46
g-index

64
all docs

64
docs citations

64
times ranked

2993
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	0.6	575
2	Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2012, 107, 253-261.	0.2	230
3	Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus. <i>Hepatology Research</i> , 2017, 47, 1072-1078.	1.8	72
4	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71
5	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018, 53, 1216-1224.	2.3	68
6	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. <i>BMC Gastroenterology</i> , 2017, 17, 96.	0.8	65
7	Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2015, 45, 771-781.	1.8	64
8	Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven nonalcoholic fatty liver disease and type 2 diabetes mellitus. <i>Hepatology Research</i> , 2017, 47, 1206-1211.	1.8	64
9	Development of hepatocellular carcinoma in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. <i>Hepatology Research</i> , 2017, 47, 1083-1092.	1.8	61
10	Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 835-843.	1.1	60
11	Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. <i>Journal of Gastroenterology</i> , 2018, 53, 140-151.	2.3	57
12	Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2019, 39, 5149-5156.	0.5	57
13	Novel antidiabetic medications for nonalcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , 2017, 47, 266-280.	1.8	53
14	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2020, 55, 428-440.	2.3	50
15	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , 2016, 51, 586-596.	2.3	49
16	Serum alanine aminotransferase predicts the histological course of nonalcoholic steatohepatitis in Japanese patients. <i>Hepatology Research</i> , 2015, 45, E53-61.	1.8	46
17	The genetic backgrounds in nonalcoholic fatty liver disease. <i>Clinical Journal of Gastroenterology</i> , 2018, 11, 97-102.	0.4	38
18	Oncogenic miR-96-5p inhibits apoptosis by targeting the caspase-9 gene in hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2018, 53, 237-245.	1.4	35

#	ARTICLE	IF	CITATIONS
19	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018, 8, 10434.	1.6	32
20	Diagnostic accuracy of FibroScan®-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , 2020, 50, 831-839.	1.8	32
21	Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2015, 45, 728-738.	1.8	28
22	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 48-60.	4.2	25
23	Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 438-448.	2.3	24
24	Insulin resistance increases the risk of incident type 2 diabetes mellitus in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2018, 48, E42-E51.	1.8	23
25	Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: A single-arm, pilot study. <i>Hepatology Research</i> , 2020, 50, 1328-1336.	1.8	23
26	Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. <i>Hepatology Research</i> , 2018, 48, 1099-1107.	1.8	22
27	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 579.	1.3	21
28	Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 1686-1692.	1.9	21
29	Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2017, 47, 1459-1468.	1.8	20
30	Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2019, 54, 160-170.	2.3	20
31	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1626-1632.	1.4	19
32	Presence of varices in patients after hepatitis C virus eradication predicts deterioration in the FIB-4 index. <i>Hepatology Research</i> , 2019, 49, 473-478.	1.8	19
33	Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice. <i>Laboratory Investigation</i> , 2022, 102, 281-289.	1.7	19
34	Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. <i>Cancers</i> , 2020, 12, 754.	1.7	18
35	Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. <i>Journal of Gastroenterology</i> , 2021, 56, 1045-1061.	2.3	18
36	Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2016, 46, 1107-1117.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2017, 47, 721-730.	1.8	16
38	Clinical and pathological features of sarcopenia-related indices in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 627-636.	1.8	16
39	FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 171.	1.8	16
40	Role of vitamin E in the treatment of non-alcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , 2021, 177, 391-403.	1.3	12
41	Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF- β 1/SMAD Signaling and Autophagy in Hepatic Stellate Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13354.	1.8	9
42	Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan. <i>Diagnostics</i> , 2020, 10, 86.	1.3	8
43	The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease. <i>Genes</i> , 2021, 12, 628.	1.0	8
44	Serum soluble sialic acid-binding immunoglobulin-like lectin-7 concentration as an indicator of liver macrophage activation and advanced fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 466-477.	1.8	7
45	PPAR α agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat. <i>Scientific Reports</i> , 2020, 10, 19578.	1.6	7
46	Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis. <i>Cancers</i> , 2021, 13, 1515.	1.7	7
47	Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFN γ /STAT1 Signaling in Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 707473.	1.3	6
48	Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. <i>Frontiers in Oncology</i> , 2021, 11, 758549.	1.3	6
49	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. <i>Journal of Gastroenterology</i> , 2022, 57, 90-98.	2.3	6
50	Potential Therapeutic Targets and Promising Agents for Combating NAFLD. <i>Biomedicines</i> , 2022, 10, 901.	1.4	6
51	Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir. <i>Hepatology Research</i> , 2015, 45, E156-60.	1.8	5
52	Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2020, 40, 3953-3960.	0.5	5
53	Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 467-474.	0.4	5
54	<p>Aging-associated impairment in metabolic compensation by subcutaneous adipose tissue promotes diet-induced fatty liver disease in mice</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1473-1492.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Loss of KAP3 decreases intercellular adhesion and impairs intracellular transport of laminin in signet ring cell carcinoma of the stomach. <i>Scientific Reports</i> , 2022, 12, 5050.	1.6	3
56	Comparison of the effect of light alcohol consumption on Japanese men with and without fatty liver. <i>Biomedical Reports</i> , 2019, 11, 191-198.	0.9	2
57	The Appropriate Opportunity for Evaluating Liver Fibrosis by Using the FIB-4 Index in Patients with Nonalcoholic Fatty Liver Disease in Japan. <i>Diagnostics</i> , 2020, 10, 842.	1.3	2
58	SOX2 enhances cell survival and induces resistance to apoptosis under serum starvation conditions through the AKT/GSK β signaling pathway in esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2021, 21, 269.	0.8	2
59	Medical checkup data analysis method based on LiNGAM and its application to nonalcoholic fatty liver disease. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102310.	3.8	2
60	Reply to: Sarcopenia definition in patients with NAFLD. <i>Journal of Gastroenterology</i> , 2019, 54, 298-298.	2.3	0
61	The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals. <i>Internal Medicine</i> , 2020, 59, 1811-1817.	0.3	0